Insomnia: Is It a Transient Symptom or Long-Lasting Functional Impairment?

Article information

Sleep Med Res. 2024;15(3):135-136
Publication date (electronic) : 2024 September 27
doi : https://doi.org/10.17241/smr.2024.02937
1Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Life Care Center for Cancer Patient, Asan Medical Center Cancer Institute, Asan Medical Center, Seoul, Korea
Corresponding Author Seockhoon Chung, MD, PhD Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, 86 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel +82-2-3010-3411 Fax +82-2-485-8381 E-mail schung@amc.seoul.kr
Received 2024 August 1; Revised 2024 September 9; Accepted 2024 September 10.

Can insomnia be classified as a transient symptom or a long-lasting functional impairment? It is an important question while we set the optimal treatment strategies for insomnia. In the clinic, most physicians guide insomnia patients to reduce or stop sleeping pills as soon as possible without considering characteristics of insomnia itself. Some patients may feel frustrated when hearing the scolding voice of the physician. They may feel guilty about taking sleeping pills and get anxious about the harmful effects of sleeping pills such as developing dementia [1] or psychiatric illness [2].

Regarding hypertension and antihypertensives, a physician plays a role in diagnosing patients and guiding them so that they could control their hypertension by taking antihypertensives after excluding some curable causes for elevated blood pressure such as weight gain, salty food, stress, and smoking [3]. Physicians will guide patients to take antihypertensives when high blood pressure still persists after correcting reversible causes. Sleep physicians should correct reversible causes for insomnia such as daily life activities, sleep-wake patterns, and other sleep disorders before prescribing sleeping pills [4]. And, physicians should guide patients to control their sleep problems with a certain tool when insomnia still remains after correcting reversible causes. From this point of view, we need to ask ourselves whether insomnia is a transient symptom or functional impairment. If we consider insomnia as a transient symptom, it is reasonable to instruct patients to take their sleeping pills transiently and guide them to quit sleeping pills as early as possible. On the other hand, if insomnia is a long-lasting functional impairment of the brain and if patients cannot sleep by themselves without certain materials (pills, vegetables, or herbal remedies), we can guide patients to control their sleep disturbance by taking sleeping pills.

Insomnia can occur temporarily when an individual suffers from severe stress or has a psychiatric or medical disease [5,6]. Vice versa, if precipitating factors in 3P model [5] can be elucidated, insomnia can resolve easily. However, if the precipitating factor cannot be easily elucidated, insomnia can last for a long time (chronic insomnia). If a woman suffers sleep disturbance while living with a husband who is stressful to her, insomnia may last unless she gets away from her husband.

On the other hand, we can find some evidence suggestive of more organic impairment and requirement of a longer time for recovery rather than a transient symptom. First, the proportion of N3 stage decreases with age [7]. It has been reported that delta activity (slow-wave sleep) decreases with aging. Aging is associated with a gradual loss of neurons such as the prefrontal cortex and the thalamus known to play key roles in generating and regulating delta waves [8]. Neurotransmitters such as gamma-aminobutyric acid (GABA) known to promote slow-wave sleep or serotonin and acetylcholine known to influence sleep architecture can be altered. Furthermore, cortical thickening in the region involved in sleep regulation can result in less pronounced delta wave activity. It means that the chance of sleeplessness is higher with increasing age.

Second, the peak level of melatonin can be decreased. It has been well reported that melatonin peak level can be decreased with aging. It is a basic reason for developing prolonged-release melatonin (PRM) as a sleeping pill [9]. However, paradoxically, PRM itself can be a evidence showing that insomnia can be a functional impairment, since patients cannot sleep well without the help of PRM, which can replenish the age-related decreased melatonin. Furthermore, among children with autism spectrum disorder or brain development disorder, nocturnal melatonin level is reduced. Such reduction is one of the causes for sleep disturbance in children [10]. It is related to pineal gland hypofunction, which can impair its ability to produce melatonin. Neurodevelopmental disorders are often associated with imbalances in neurotransmitters and neurochemicals, which can affect the function of the pineal gland and melatonin production. Certain genetic mutations associated with neurodevelopmental disorders may directly or indirectly affect melatonin synthesis.

From this point of view, some of insomnia patients suffer from lifelong insomnia and may require sleep aids for long-term, and that these patients should not be given the same one unified rule—quit sleep aids as early as possible. We should not tell patients to stop or quit their sleeping pills without considering characteristics of insomnia itself. Rather, clinicians should classify patients into “patients who can sleep without medication” and “patients who cannot sleep without medication.” Without this classification, our guidance to reduce or quit the sleeping pills can be a sword to some patients who cannot sleep without medication due to functional impairment of brain. Sleep physicians should guide “patients who can sleep without medications” to get the help. Non-pharmacological treatments, such as cognitive-behavioral therapy for insomnia (CBT-I), are effective for many “patients who can sleep without medication.” However, for “those who cannot sleep without medication,” we need to develop optimal strategies for the safe and effective use of sleeping pills. Understanding the characteristics of insomnia can help in creating these strategies, guiding patients on the scientific use of sleeping pills, including when to take them and how to discontinue their use appropriately.

Notes

Conflicts of Interest

Seockhoon Chung, the Editorial Committee Chair of Sleep Medicin Research, was not involved in the editorial evaluation or decision to publish this article.

Funding Statement

None

Acknowledgements

None

References

1. Wawrziczny E, Buquet A, Picard S. Use of hypnosis in the field of dementia: a scoping review. Arch Gerontol Geriatr 2021;96:104453.
2. Chung KH, Li CY, Kuo SY, Sithole T, Liu WW, Chung MH. Risk of psychiatric disorders in patients with chronic insomnia and sedativehypnotic prescription: a nationwide population-based follow-up study. J Clin Sleep Med 2015;11:543–51.
3. Kario K, Hoshide S, Mogi M. Hypertension treatment up-date on world hypertension day 2024: current status and future prospects in Asia. Hypertens Res 2024;47:1763–5.
4. Choi H, Youn S, Um YH, Kim TW, Ju G, Lee HJ, et al. Korean clinical practice guideline for the diagnosis and treatment of insomnia in adults. Psychiatry Investig 2020;17:1048–59.
5. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am 1987;10:541–53.
6. Chung S, Ahmed O, Cho E, Bang YR, Ahn J, Choi H, et al. Psychometric properties of the insomnia severity index and its comparison with the shortened versions among the general population. Psychiatry Investig 2024;21:9–17.
7. Espiritu JR. Aging-related sleep changes. Clin Geriatr Med 2008;24:1–14.
8. Uygun DS, Basheer R. Circuits and components of delta wave regulation. Brain Res Bull 2022;188:223–32.
9. Wade A, Downie S. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Investig Drugs 2008;17:1567–72.
10. Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol 2018;28:699–710.

Article information Continued